In sensitivity analysis we adjusted the main analysis of CYP2C19 LoF carriers for history of stroke, TIA, MI/angina, PAD, and atrial fibrillation to assess whether disease indication modified the effect of genotype on ischaemic stroke risk and found the estimate to be unaffected (HR 1.56, 95% CI 1.06 to 2.31, p=0.024). This evidence concerns the gene CYP2C19 and Stroke.